The inluence of selective COX-2 inhibitor on phase of healing surgical wounds: proliferation and secretion of bFGF by endothelial cells

The process of wound healing consists of the following phases: inlammation, proliferation, remodeling. Non-steroidal antiinlammatory drugs may be important in this process, especially in a stage called angiogenesis. For this reason, it was decided to investigate the effect of selective COX-2 (cyclooxygenase 2) inhibitor (NS-398) on the proliferation of endothelial cells and their ability to secrete bFGF (ibroblast growth factor) for vascular endothelial cells (hMEC-1). For determination of the secretion of bFGF in a cell line hMEC-1 immunosorbent ELISA assays were used. In turn, the cell proliferation assay was performed using the MTT method. Using MTT method, it was found that NS-398 at 10 μM did not affect cell viability. Whereas selective COX-2 inhibitor at 100 μM decreased cell viability in a statistically signiicant manner and inhibited the proliferative effect of 100 μg/mL LPS at concentrations of 10 and 100 μM. In the further step, application of NS-398 (10 and 100 μM) with LPS (100 μg/mL; inlammatory environment) reduced the secretion of bFGF in a statistically signiicant manner. The investigations showed that NS-398 has an antiangiogenic effect which is based on reducing the proliferation of vascular endothelial cells and inhibiting the secretion of bFGF- factor responsible for angiogenesis during wound healing.